Ken Griffin Poly Pid Ltd. Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.66 - $38.7 $7,671 - $449,848	-11,624 Reduced 95.48%	550 $0
Q3 2022 Nov 14, 2022	SELL	$1.06 - $36.9 $14,965 - $520,954	-14,118 Reduced 53.7%	12,174 $14,000
Q2 2022 Aug 15, 2022	SELL	$4.35 - $5.76 $34,747 - $46,010	-7,988 Reduced 23.3%	26,292 $122,000
Q1 2022 May 16, 2022	BUY	$3.92 - $6.25 $86,537 - $137,975	22,076 Added 180.89%	34,280 $187,000
Q4 2021 Feb 14, 2022	BUY	$5.52 - $8.42 $67,366 - $102,757	12,204 New	12,204 $0
Q1 2021 May 17, 2021	SELL	$8.92 - $15.5 $168,222 - $292,314	-18,859 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$8.89 - $13.5 $167,656 - $254,596	18,859 New	18,859 $188,000
Q3 2020 Nov 16, 2020	SELL	$11.0 - $17.33 $1.01 Million - $1.58 Million	-91,451 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$18.03 - $19.0 $1.65 Million - $1.74 Million	91,451 New	91,451 $1.65 Million

Ticker PYPD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 19,551,200
Market Cap $69.6M
Description
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well a...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.